SCHEMBL1640222

SCHEMBL1640222

NC(CC1=CC(=O)C(=O)C=C1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.44
PKM P14618 2/20 0.44
PTGS1 P23219 2/20 0.44
ALPI P09923 1/20 0.44
XIAP P98170 1/20 0.44
USP2 O75604 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ALOX15 P16050 2/20 0.41
HIF1A Q16665 2/20 0.41
KDM4E B2RXH2 2/20 0.41
RECQL P46063 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 2/20 0.41
RGS12 O14924 1/20 0.41
CYP2C9 P11712 1/20 0.41
NFKB1 P19838 1/20 0.41
CASP1 P29466 1/20 0.41
BRCA1 P38398 1/20 0.41
THPO P40225 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14441259 1.00 SLC7A5 (0.44) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL5300667 1.00 SLC7A5 (0.44) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL14023473 0.84 SLC7A5 (0.41) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL1076502 0.74 SLC7A5 (0.44) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL3278753 0.74 SLC7A5 (0.41) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL6009735 0.71 USP2 (0.42) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL23996206 0.71 MAPT (0.39) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL29280376 0.70 SLC7A5 (0.46) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL4994581 0.70 SLC7A5 (0.46) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL25737316 0.69 SLC7A5 (0.37) SLC7A5PKMPTGS1ALPIXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276107-A1 HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) 2025-09-04 US claimed
US-20250176872-A1 SYSTEMS AND METHODS FOR SENSING LEVODOPA DEXCOM, INC. (US) 2025-06-05 US claimed
WO-2024258183-A1 SKIN SOOTHING OR ANTI-INFLAMMATORY COMPOSITION COMPRISING METAL-PHENOLIC COMPLEX AND MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO claimed
WO-2024258187-A1 COMPOSITION FOR STRENGTHENING HAIR ROOTS COMPRISING METAL-PHENOLIC COMPLEX AND MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO claimed
WO-2024258190-A1 HAIR DYE COMPOSITION FOR PREMATURE GRAY HAIR AND METHOD FOR PREPARING SAME 코스맥스 주식회사 2024-12-19 WO claimed
WO-2024258193-A1 METAL-PHENOL COMPLEX AND DYEING COMPOSITION COMPRISING MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO claimed
EP-4436989-A1 SKIN MIMICRY COMPOSITIONS AND IMPLANTS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2024-10-02 EP claimed
WO-2023095134-A1 SKIN MIMICRY COMPOSITIONS AND IMPLANTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-06-01 WO claimed
US-12611369-B2 Skin mimicry compositions and implants YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2026-04-28 US disclosed
US-20260108446-A1 HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS GERMANAS JURIS (US) 2026-04-23 US disclosed
EP-4729513-A1 A-KETO ACID AMIDE OR SUBSTITUTED OXALIC ACID AMIDE ESTER COMPOUND AND COMPOSITION THEREOF Nanjing Chempion Biotechnology Co., Ltd. (CN) 2026-04-22 EP disclosed
EP-4727954-A1 HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS, THEIR USES AND INTERMEDIATES FOR THEIR PREPARATION Victoria Link Limited (NZ) 2026-04-22 EP disclosed
US-12605323-B2 Composition for inhibiting hair graying, and use thereof LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2026-04-21 US disclosed
EP-4724565-A2 METHODS FOR PRODUCING MODIFIED BETALAINS IN YEAST Danmarks Tekniske Universitet (DK) 2026-04-15 EP disclosed
US-20080287536-A1 Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes BIODERM RESEARCH (US) 2008-11-20 US disclosed
US-20080286219-A1 Hydroquinone derivative skin brightening compounds EASTMAN CHEMICAL COMPANY 2008-11-20 US disclosed
US-7427690-B2 Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration BIODERM RESEARCH (US) 2008-09-23 US disclosed
EP-1073418-B1 AQUEOUS COMPOSITION COMPRISING ACTIVE INGREDIENTS FOR THE DE-PIGMENTATION OF THE SKIN UNIVERA PHARM INC (US) 2007-12-05 EP disclosed
US-20070099886-A1 Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration BIODERM RESEARCH (US) 2007-05-03 US disclosed
US-5859198-A ADHESIVE PROTEINS ISOLATED FROM ALGAE WHICH DO NOT CONTAIN HYDROXYPROLINE OR 3,4-DIHYDROXYPHENYL-L-ALANINE BIOTA LTD. (IL) 1999-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080286219-A1 Hydroquinone derivative skin brightening compounds NQO1, CUTA, TYR SLC7A5 2248/4885PKM 3475/4885PTGS1 421/4885
US-20260108446-A1 HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS TYR, TFEB, MC1R SLC7A5 748/4885PKM 870/4885PTGS1 1556/4885
US-20080287536-A1 Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes MMP17, MC1R, TYR SLC7A5 150/4885PKM 2063/4885PTGS1 436/4885
US-12605323-B2 Composition for inhibiting hair graying, and use thereof CTNND1, CTNNB1, GSK3B SLC7A5 430/4885PKM 4046/4885PTGS1 2229/4885
US-12611369-B2 Skin mimicry compositions and implants TYR, KRT18, MARK1 SLC7A5 1683/4885PKM 54/4885PTGS1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.